TABLE 3

Comparative Biodistribution (%ID/g and Tumor-to-Nontumor Ratios) of Pretargeted ¹²⁴I-Peptide Compared with ¹²⁴I-Anti-CEA Fab′ and ¹⁸F-FDG Based on Necropsy Data

	%ID/g (mean ± SD)
	Pretargeted ¹²⁴I-peptide			¹²⁴I-Anti-CEA Fab′ (12 μg)			¹²⁴I-Anti-CEA Fab′ (100 μg), 24 h (n = 4)	¹⁸F-FDG^*, 2.0 h (n = 3)
Tumor or organ	1 h (n = 5)	3 h (n = 5)	24 h (n = 5)	1 h (n = 5)	3 h (n = 5)	24 h (n = 5)	¹²⁴I-Anti-CEA Fab′ (100 μg), 24 h (n = 4)	¹⁸F-FDG^*, 2.0 h (n = 3)
Tumor	15.4 ± 3.1	18.2 ± 4.6	12.5 ± 1.1	5.7 ± 0.4	5.3 ± 0.6	0.8 ± 0.2	0.7 ± 0.2	4.8 ± 1.14
	0.15 ± 0.02^†	0.19 ± 0.03	0.20 ± 0.04	0.09 ± 0.01	0.10 ± 0.03	0.08 ± 0.02	0.08 ± 0.01	0.41 ± 0.11
Liver	0.6 ± 0.1	0.6 ± 0.2	0.3 ± 0.02	8.2 ± 1.6	3.2 ± 0.5	0.3 ± 0.1	0.1 ± 0.03	0.6 ± 0.1
	(26.3 ± 7.8)^‡	(31.2 ± 5.5)	(43 ± 6)	(0.7 ± 0.2)	(1.7 ± 0.3)	(3.0 ± 1.1)	(6.4 ± 1.9)	(8.7 ± 1.1)
Spleen	0.6 ± 0.1	0.6 ± 0.2	0.2 ± 0.03	17.7 ± 3.9	6.3 ± 1.6	0.2 ± 0.04	0.1 ± 0.02	1.9 ± 0.2
	(25.4 ± 6.4)	(34.6 ± 8.9)	(57 ± 10)	(0.3 ± 0.1)	(0.9 ± 0.2)	(3.2 ± 0.6)	(9.3 ± 1.9)	(2.6 ± 0.8)
Kidney	4.8 ± 0.5	4.3 ± 1.5	2.7 ± 0.3	68.7 ± 7.6	9.2 ± 2.3	0.4 ± 0.2	0.2 ± 0.04	0.7 ± 0.2
	(3.3 ± 0.8)	(4.5 ± 1.3)	(4.6 ± 0.5)	(0.1 ± 0.02)	(0.6 ± 0.1)	(2.6 ± 1.4)	(3.0 ± 0.6)	(7.1 ± 0.4)
Lungs	1.4 ± 0.2	1.1 ± 0.3	0.3 ± 0.03	2.9 ± 0.3	2.9 ± 0.3	0.05 ± 0.01	0.04 ± 0.02	1.7 ± 0.2
	(11.6 + 3.6)	(17.1 ± 2.9)	(44 ± 6)	(2.0 ± 0.2)	(1.8 ± 0.3)	(16 ± 6)	(20 ± 5)	(2.9 ± 0.4)
Blood	1.7 ± 0.2	1.1 ± 0.4	0.05 ± 0.01	4.6 ± 0.3	4.9 ± 0.4	0.07 ± 0.00	0.05 ± 0.03	0.30 ± 0.06
	(9.1 ± 2.6)	(17.9 ± 3.5)	(238 ± 48)	(1.3 ± 0.07)	(1.1 ± 0.2)	(11 ± 3)	(15 ± 5)	(16.0 ± 0.4)
Stomach^§	3.9 ± 0.5	4.0 ± 2.2	0.2 ± 0.1	20.8 ± 4.2	32.4 ± 2.6	0.5 ± 0.2	0.3 ± 0.2	1.8 ± 0.9
	(4.0 ± 0.9)	(6.0 ± 3.9)	(72 ± 24)	(0.3 ± 0.05)	(0.2 ± 0.02)	(1.8 ± 1.0)	(3.1 ± 1.0)	(2.9 ± 0.4)

↵* Data from MSKCC animals, whereas all other data were obtained from CMMI animals.
↵† Italicized values are tumor weights in grams.
↵‡ Nonitalicized values in parentheses are tumor-to-nontumor ratios.
↵§ With contents.